A Critical Evaluation of Terpenoid Signaling at Cannabinoid CB1 Receptors in a Neuronal Model.
CB1
G protein-coupled receptor
cannabinoid
cannabis
terpene
terpenoid
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
received:
12
08
2022
revised:
30
08
2022
accepted:
31
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
In addition to phytocannabinoids, cannabis contains terpenoids that are claimed to have a myriad of effects on the body. We tested a panel of five common cannabis terpenoids, myrcene, linalool, limonene, α-pinene and nerolidol, in two neuronal models, autaptic hippocampal neurons and dorsal root ganglion (DRG) neurons. Autaptic neurons express a form of cannabinoid CB1 receptor-dependent retrograde plasticity while DRGs express a variety of transient receptor potential (TRP) channels. Most terpenoids had little or no effect on neuronal cannabinoid signaling. The exception was nerolidol, which inhibited endocannabinoid signaling. Notably, this is not via inhibition of CB1 receptors but by inhibiting some aspect of 2-arachidonoylglycerol (2-AG) production/delivery; the mechanism does not involve reducing the activity of the 2-AG-synthesizing diacylglycerol lipases (DAGLs). Nerolidol was also the only terpenoid that activated a sustained calcium response in a small (7%) subpopulation of DRGs. In summary, we found that only one of five terpenoids tested had notable effects on cannabinoid signaling in two neuronal models. Our results suggest that a few terpenoids may indeed interact with some components of the cannabinoid signaling system and may therefore offer interesting insights upon further study.
Identifiants
pubmed: 36080421
pii: molecules27175655
doi: 10.3390/molecules27175655
pmc: PMC9457791
pii:
doi:
Substances chimiques
Cannabinoid Receptor Agonists
0
Cannabinoids
0
Endocannabinoids
0
Hallucinogens
0
Receptor, Cannabinoid, CB1
0
Receptors, Cannabinoid
0
Terpenes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : DA011322 , DA021696
Pays : United States
Références
Eur J Med Chem. 2018 Sep 5;157:198-228
pubmed: 30096653
Phytomedicine. 2010 Jul;17(8-9):679-83
pubmed: 19962290
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):305-317
pubmed: 33376801
J Neurochem. 1991 Sep;57(3):782-94
pubmed: 1861150
Br J Pharmacol. 2011 Aug;163(7):1479-94
pubmed: 21175579
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
pubmed: 2308954
Front Cell Neurosci. 2014 Aug 01;8:195
pubmed: 25136293
Behav Brain Res. 2006 Sep 25;172(2):240-9
pubmed: 16780969
Asian-Australas J Anim Sci. 2012 Oct;25(10):1411-8
pubmed: 25049497
Planta Med. 2016 Feb;82(3):211-6
pubmed: 26584457
Front Mol Neurosci. 2019 Jan 15;11:487
pubmed: 30697147
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
J Cell Biol. 2003 Nov 10;163(3):463-8
pubmed: 14610053
Neurosci Bull. 2018 Feb;34(1):120-142
pubmed: 29282613
Phytomedicine. 2002 Dec;9(8):709-14
pubmed: 12587690
Nat Chem Biol. 2012 Dec;8(12):999-1007
pubmed: 23103940
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):177-182
pubmed: 31579834
J Physiol. 2005 Dec 1;569(Pt 2):501-17
pubmed: 16179366
Br J Pharmacol. 2000 Jan;129(2):227-30
pubmed: 10694225
Am J Chin Med. 2015;43(4):731-42
pubmed: 26119957
J Neuroimmunol. 2020 Mar 15;340:577145
pubmed: 31945593
Mol Pharmacol. 2013 Aug;84(2):296-302
pubmed: 23748223
Proc Natl Acad Sci U S A. 1976 Nov;73(11):4225-9
pubmed: 186792
Expert Rev Clin Pharmacol. 2020 Aug;13(8):835-845
pubmed: 32116073
Neuroscience. 2009 Sep 29;163(1):190-201
pubmed: 19501632
Toxicol Res. 2017 Apr;33(2):97-106
pubmed: 28443180
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7834-8
pubmed: 1679238
Eur J Neurosci. 2004 Nov;20(9):2276-82
pubmed: 15525269
Pain. 2020 Jul;161(7):1497-1517
pubmed: 32197039
Mol Pharmacol. 2009 Dec;76(6):1220-7
pubmed: 19767452
Pharmacol Res. 2018 Mar;129:475-481
pubmed: 29158048
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
J Neurosci. 2001 Feb 15;21(4):1104-9
pubmed: 11160380
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):165-176
pubmed: 31559333
Nat Rev Neurosci. 2003 Nov;4(11):873-84
pubmed: 14595399
Pharmacol Biochem Behav. 2013 Jan;103(3):450-4
pubmed: 22995322
J Forensic Sci. 2010 Sep;55(5):1209-17
pubmed: 20487147
J Physiol. 2007 Feb 1;578(Pt 3):773-85
pubmed: 17110416
J Neurophysiol. 2009 Aug;102(2):1160-71
pubmed: 19494194
Pharmacol Res. 2015 Sep;99:370-6
pubmed: 26211948
Ann Pharm Fr. 1972 Sep;30(9):611-6
pubmed: 4662184
Channels (Austin). 2019 Dec;13(1):344-366
pubmed: 31446830
Front Pharmacol. 2020 Mar 25;11:359
pubmed: 32269529
BMC Res Notes. 2016 Feb 11;9:82
pubmed: 26864470
J Lipid Res. 2011 Apr;52(4):826-32
pubmed: 21270098
ACS Chem Neurosci. 2014 Nov 19;5(11):1131-41
pubmed: 25029033
Br J Pharmacol. 2017 Aug;174(15):2545-2562
pubmed: 28516479
J Neurosci. 1993 Feb;13(2):867-73
pubmed: 7678862
J Pharm Pharmacol. 2000 Jul;52(7):895-902
pubmed: 10933142
Phytomedicine. 2009 Apr;16(4):303-7
pubmed: 18824339
Curr Neuropharmacol. 2020;18(2):87-96
pubmed: 31481004
Molecules. 2021 Sep 02;26(17):
pubmed: 34500785
MicroPubl Biol. 2020 Jan 28;2020:
pubmed: 32550514
Biol Pharm Bull. 2002 Dec;25(12):1629-33
pubmed: 12499653